Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31359427 | 0.75 | TRPA1 (0.41) | TRPA1PIM1CSNK1A1CDK5ROCK1 | |
| SCHEMBL1319720 | 0.75 | TRPA1 (0.41) | TRPA1PIM1CSNK1A1CDK5ROCK1 | |
| SCHEMBL5950996 | 0.74 | TRPA1 (0.43) | TRPA1PIM1CSNK1A1CDK5ROCK1 | |
| SCHEMBL2960350 | 0.72 | TRPA1 (0.42) | TRPA1PIM1CSNK1A1CDK5ROCK1 | |
| SCHEMBL2971904 | 0.71 | TRPA1 (0.41) | TRPA1PIM1CSNK1A1CDK5ROCK1 | |
| SCHEMBL2481925 | 0.70 | TRPA1 (0.38) | TRPA1PIM1CSNK1A1CDK5ROCK1 | |
| SCHEMBL2973265 | 0.70 | TRPA1 (0.38) | TRPA1PIM1CSNK1A1CDK5ROCK1 | |
| SCHEMBL2971532 | 0.70 | TRPA1 (0.38) | TRPA1PIM1CSNK1A1CDK5ROCK1 | |
| SCHEMBL7199649 | 0.68 | PTGS2 (0.41) | TRPA1 | |
| SCHEMBL2967415 | 0.68 | TRPA1 (0.36) | TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763562-B2 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2007-06-14 | — | — | US | disclosed |
| WO-2006065809-A2 | HETEROATOM BRIDGED METALLOCENE COMPOUNDS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135597-A1 | Heteroatom bridged metallocene compounds for olefin polymerization | AP2M1, AP1M1, PYM1 | TRPA1 438/4885PIM1 4466/4885CSNK1A1 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.